News

Artificial intelligence (AI) infrastructure stocks continue to drive this market, and with spending expected to ramp up even further in the coming years, there is no reason to think that these

On Nov. 14, 2025, 4D Advisors, LLC disclosed in a regulatory filing that it sold out its entire position in Masimo (NASDAQ:MASI). The sale was valued at $7.57 million.

According to a filing with the

Identifying good companies isn't always easy, but there are shortcuts you can take.

One of my favorite is focusing on companies that have a long history of annual dividend increases behind them

The biotech industry is notoriously volatile. Drugmakers often face significant challenges that send their stocks plummeting. Sometimes that creates an attractive entry point, provided we can

Pfizer (NYSE: PFE) has been southbound for the past three years. Following its success in the coronavirus market, which made it the first company in the biopharma industry to generate $100 billion

Advanced Micro Devices (NASDAQ: AMD) stock has battled back from substantial sell-offs early this morning and is now in the green on the day's trading. The company's share price was up 0.3% as of

The stock of pharmaceutical company Amgen (NASDAQ: AMGN) didn't exactly have a banner trading session on Thursday. In closing the day nearly flat, however, to notch a slight beat on the S&P 500

Palantir Technologies has delivered outstanding gains of 135% to investors in 2025 as of this writing, but it looks like the company's valuation is going to weigh on its stock price. This explains

Biotech stocks have performed well this year. The SPDR S&P Biotech ETF -- an industry benchmark -- is up 21% this year. Two giants of the industry that have helped drive that performance are Amgen

Merck (NYSE: MRK) has a $210 billion market cap. Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful histories behind them. But

Drug giant Eli Lilly (NYSE: LLY) now has the best-selling drug on the planet. It's a GLP-1 dual receptor agonist called tirzepatide, which Lilly sells as Mounjaro for treating type 2 diabetes and

As an old investing adage goes: Investors have lost more reaching for yield than at the point of a gun. That may sound a bit dramatic, but when you think of all the yield trap stocks -- high-yield

Shares of Advanced Micro Devices (NASDAQ: AMD) climbed 9% on Wednesday after the artificial intelligence (AI) chipmaker laid out a promising growth trajectory for investors at its Financial Analyst

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

Meta Platforms (NASDAQ: META) has come a long way from its origins as a platform to connect students to its current status as a social media powerhouse and leader in the ongoing artificial

All things considered, broader equities have performed pretty well in 2025, with the S&P 500 up 14% since the beginning of the year. It seems so long ago that the index flirted with bear-market

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you

Innovative biopharmaceutical company Metsera (NASDAQ: MTSR) has been climbing all year. It went public on Feb. 3 of this year, priced at $18 per share, and immediately climbed above $27. It had been

On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year high, on continued momentum from a far better-than-expected quarterly earnings report. The immediate catalyst was a post-earnings price target

Shares in Theravance Biopharma (NASDAQ: TBPH) surged by more than 21% as of noontime ET today. The move comes as the market digests the previous day's excellent third-quarter results and corporate

Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is

Investing in individual stocks can be a rocky road. Our job as investors is to find high-quality stocks at great prices with bright futures.

In today's video, I will be discussing three stocks